Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. See WA, Wirth MP, McLeod DG, Iversen P, Klimberg I, Gleason D, Chodak G, Montie J, Tyrrell C, Wallace DM, Delaere KP, Vaage S, Tammela TL, Lukkarinen O, Persson BE, Carroll K, Kolvenbag GJ; Casodex Early Prostate Cancer Trialist Group, Medical College of Wisconsin, Milwaukee, WI - J Urol 2002;168:429-43

Author： Trump D.L.  

Publisher： Elsevier

ISSN： 1078-1439

Source： Urologic Oncology: Seminars and Original Investigations, Vol.21, Iss.5, 2003-09, pp. : 408-409

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The bicalutamide Early Prostate Cancer Program - Demography

By See W.A.   McLeod D.   Iversen P.   Wirth M.  

Urologic Oncology: Seminars and Original Investigations, Vol. 6, Iss. 2, 2001-03 ,pp. : 43-47

Elsevier

Access to resources Recommend Favorite

The Management of Localized or Locally Advanced Prostate Cancer

By Wirth M.P.   Froehner M.  

American Journal of Cancer, Vol. 1, Iss. 6, 2002-01 ,pp. : 387-396

Adis International

Access to resources Recommend Favorite

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B, Zoledronic Acid Prostate Cancer Study Group, Uro-Oncology Clinic, Centre Hospitalier de l'Universite, de Montreal, Hopital Notre-Dame, Montreal, Quebec, Canada - J Natl Cancer Inst 2002;94:1458-1468

By Trump D.L.  

Urologic Oncology: Seminars and Original Investigations, Vol. 21, Iss. 5, 2003-09 ,pp. : 408-408

Elsevier

Access to resources Recommend Favorite

Cost-effectiveness of the addition of early hormonal therapy in locally advanced prostate cancer - results decisively determined by the cut-off time-point chosen for the analysis

By Neymark N.   Adriaenssen I.   Gorlia T.   Caleo S.   Bolla M.   Brochon D.  

European Journal of Cancer, Vol. 37, Iss. 14, 2001-09 ,pp. : 1768-1774

Elsevier

Access to resources Recommend Favorite

Docetaxel as Neoadjuvant Therapy in Early-Stage or Locally Advanced Breast Cancer: A Viewpoint by Steven D. Heys and Nicole J. McCarthy

By Heys Steven D.  

American Journal of Cancer, Vol. 5, Iss. 3, 2006-01 ,pp. : 207-209

Adis International

Access to resources Recommend Favorite